Artios doses first patient with Polθ Inhibitor ART4215
Many cancers alter their DDR pathways to drive genomic instability and increase mutational burden in their DNA. This causes protein changes that enable the cancer cells to evolve, adapt, and become resistant to treatment.
Artios is a leading independent DDR Company with a strong pipeline of novel cancer therapies in development with first-in-class and best-in-class potential. Our cutting-edge DDR programmes have applications across a broad range of cancers.
The Artios team has many years of experience identifying and bringing to clinic high value DDR drugs. By working with industry-leading partners and investors we aim to push the boundaries in the fight against cancer.